Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.40 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.38 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652201 | 0.96 | FLT3 (0.43) | FLT3AKT3PRSS12F9KDM4E | |
| SCHEMBL5648383 | 0.89 | FLT3 (0.44) | FLT3AKT3PRSS12PTGDR2KDM4E | |
| SCHEMBL5648386 | 0.87 | FLT3 (0.44) | FLT3AKT3PRSS12KDM4EHSD17B10 | |
| SCHEMBL5650339 | 0.87 | ALDH1A1 (0.49) | KDM4EHSD17B10 | |
| SCHEMBL5652805 | 0.83 | MEN1 (0.51) | KDM4EHSD17B10 | |
| SCHEMBL5650343 | 0.83 | ALDH1A1 (0.49) | KDM4EHSD17B10 | |
| SCHEMBL5651793 | 0.81 | PRSS12 (0.56) | FLT3PRSS12PTGDR2 | |
| SCHEMBL5652813 | 0.80 | L3MBTL1 (0.51) | KDM4EHSD17B10 | |
| SCHEMBL5651361 | 0.80 | FLT3 (0.54) | FLT3PRSS12 | |
| SCHEMBL5649147 | 0.78 | FLT3 (0.53) | FLT3PRSS12F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | FLT3 1968/4885AKT3 1338/4885PRSS12 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.